# rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors

> **NCT00902083** · PHASE4 · UNKNOWN · sponsor: **Shenzhen SiBiono GeneTech Co.,Ltd** · enrollment: 600 (estimated)

## Conditions studied

- Advanced Oral and Maxillofacial Malignant Tumors

## Interventions

- **DRUG:** p53 gene with surgery
- **PROCEDURE:** surgery
- **DRUG:** p53 with chemotherapy
- **DRUG:** p53 gene therapy

## Key facts

- **NCT ID:** NCT00902083
- **Lead sponsor:** Shenzhen SiBiono GeneTech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2012-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902083, "rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00902083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*